MX2019014054A - Profarmacos de glucuronida de inhibidores de la cinasa janus. - Google Patents

Profarmacos de glucuronida de inhibidores de la cinasa janus.

Info

Publication number
MX2019014054A
MX2019014054A MX2019014054A MX2019014054A MX2019014054A MX 2019014054 A MX2019014054 A MX 2019014054A MX 2019014054 A MX2019014054 A MX 2019014054A MX 2019014054 A MX2019014054 A MX 2019014054A MX 2019014054 A MX2019014054 A MX 2019014054A
Authority
MX
Mexico
Prior art keywords
glycuronide
pro
drugs
compounds
inhibitors
Prior art date
Application number
MX2019014054A
Other languages
English (en)
Spanish (es)
Inventor
D Long Daniel
A A Wilton Donna
Hudson Ryan
Loo Mandy
J Brassil Patrick
Original Assignee
Theravance Biopharma R&D Ip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D Ip Llc filed Critical Theravance Biopharma R&D Ip Llc
Publication of MX2019014054A publication Critical patent/MX2019014054A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26Acyclic or carbocyclic radicals, substituted by hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/12Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by acids having the group -X-C(=X)-X-, or halides thereof, in which each X means nitrogen, oxygen, sulfur, selenium or tellurium, e.g. carbonic acid, carbamic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02Heterocyclic radicals containing only nitrogen as ring hetero atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
MX2019014054A 2017-05-23 2018-05-22 Profarmacos de glucuronida de inhibidores de la cinasa janus. MX2019014054A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762509847P 2017-05-23 2017-05-23
PCT/US2018/033818 WO2018217700A1 (en) 2017-05-23 2018-05-22 Glucuronide prodrugs of janus kinase inhibitors

Publications (1)

Publication Number Publication Date
MX2019014054A true MX2019014054A (es) 2020-02-05

Family

ID=62621001

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019014054A MX2019014054A (es) 2017-05-23 2018-05-22 Profarmacos de glucuronida de inhibidores de la cinasa janus.

Country Status (14)

Country Link
US (2) US10745405B2 (enExample)
EP (1) EP3609899A1 (enExample)
JP (1) JP2020520955A (enExample)
KR (1) KR20200010440A (enExample)
CN (1) CN110662747A (enExample)
AU (1) AU2018273866B2 (enExample)
BR (1) BR112019024509A2 (enExample)
CA (1) CA3063963A1 (enExample)
IL (1) IL270693A (enExample)
MX (1) MX2019014054A (enExample)
NZ (1) NZ759764A (enExample)
PH (1) PH12019502605A1 (enExample)
RU (1) RU2019142472A (enExample)
WO (1) WO2018217700A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111094314B (zh) * 2018-08-15 2022-08-12 江苏豪森药业集团有限公司 含有葡糖苷酸衍生物jak抑制剂的前药及其制备方法和应用
CN111196831B (zh) * 2020-01-20 2023-05-09 山西医科大学 一种呋喃酚葡萄糖醛酸结合物的制备方法
WO2023018954A1 (en) * 2021-08-12 2023-02-16 Concert Pharmaceuticals, Inc. Treatment of jak-inhibition-responsive disorders with prodrugs of jak inhibitors
JP2025505812A (ja) * 2022-02-21 2025-02-28 オンクオリティ ファーマシューティカルズ チャイナ リミテッド 化合物及びその用途
EP4507691A2 (en) * 2022-04-15 2025-02-19 The Regents Of The University Of Michigan Jak inhibitor analogs, formulations, and uses thereof
CN115073543B (zh) * 2022-07-20 2022-11-15 北京普祺医药科技股份有限公司 一种jak抑制剂的化合物前药及其制备与应用
WO2024133631A1 (en) 2022-12-22 2024-06-27 Krka, D.D., Novo Mesto Veterinary composition comprising oclacitinib
WO2024148049A1 (en) * 2023-01-04 2024-07-11 Kymera Therapeutics, Inc. Irak4 degraders and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993022334A1 (en) 1992-05-04 1993-11-11 Sri International Pharmaceutical compositions and methods for colonic delivery of corticosteroids
US5811388A (en) 1995-06-07 1998-09-22 Cibus Pharmaceutical, Inc. Delivery of drugs to the lower GI tract
AU777911B2 (en) 1999-12-10 2004-11-04 Pfizer Products Inc. Pyrrolo(2,3-d)pyrimidine compounds
US7798257B2 (en) 2004-04-30 2010-09-21 Smith International, Inc. Shaped cutter surface
DK3184526T3 (en) 2005-12-13 2019-01-14 Incyte Holdings Corp PYRROLO [2,3-D] PYRIMIDINE DERIVATIVES AS A JANUS-KINASE INHIBITOR
ES2602577T3 (es) 2008-03-11 2017-02-21 Incyte Holdings Corporation Derivados de azetidina y ciclobutano como inhibidores de JAK
RU2493157C2 (ru) 2008-08-20 2013-09-20 Пфайзер Инк. ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА
CA2777114C (en) 2009-10-09 2018-10-23 Incyte Corporation Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
EP2515913A2 (en) 2009-12-23 2012-10-31 Glycomyr Inc. Use of vitamin d glycosides and sulfates for treatment of disease
CN102724967A (zh) 2009-12-31 2012-10-10 安龙制药公司 包括可释放的脲连接体的含芳香胺化合物的聚合缀合物
CN102822177A (zh) 2010-02-05 2012-12-12 美国辉瑞有限公司 吡咯并[2,3-d]嘧啶脲化合物
CA2913752A1 (en) 2013-05-31 2014-12-04 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
EA035816B1 (ru) 2015-11-24 2020-08-14 ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи Пролекарства jak-ингибирующего соединения для лечения воспалительного заболевания желудочно-кишечного тракта
CN106496233B (zh) 2016-09-26 2018-05-15 东南大学 吡咯并嘧啶类化合物、其制备方法及其用途

Also Published As

Publication number Publication date
PH12019502605A1 (en) 2020-10-26
AU2018273866A1 (en) 2019-12-19
RU2019142472A3 (enExample) 2021-09-23
WO2018217700A1 (en) 2018-11-29
BR112019024509A2 (pt) 2020-06-23
NZ759764A (en) 2022-07-01
RU2019142472A (ru) 2021-06-24
US20180339990A1 (en) 2018-11-29
IL270693A (en) 2020-01-30
CA3063963A1 (en) 2018-11-29
AU2018273866B2 (en) 2021-09-30
EP3609899A1 (en) 2020-02-19
KR20200010440A (ko) 2020-01-30
CN110662747A (zh) 2020-01-07
JP2020520955A (ja) 2020-07-16
US10745405B2 (en) 2020-08-18
US20210032250A1 (en) 2021-02-04

Similar Documents

Publication Publication Date Title
MX2019014054A (es) Profarmacos de glucuronida de inhibidores de la cinasa janus.
CO2018011408A2 (es) Compuestos de pirimidina como inhibidores de la quinasa jak
CO2017012267A2 (es) Compuestos de naftiridina como inhibidores de la quinasa jak
CL2018000952A1 (es) Compuestos útiles como inmunomoduladores
MX2017003695A (es) Pirimidinonas como inhibidores del factor xia.
MX388751B (es) Compuestos de imidazo-piperidina fusionada como inhibidores de jak.
DOP2020000083A (es) Compuesto de pirimidina como inhibidor de las janocinasas
UY35975A (es) Macrociclos con grupos p2? heterocíclicos como inhibidores del factor xia
EA201691625A1 (ru) Ароматические гетероциклические соединения как противовоспалительные соединения
BR112015004111A2 (pt) novos derivados bicíclicos
UY35467A (es) Compuestos orgánicos
UY34960A (es) Dihidropiridona p1 como inhibidores del factor xia
UY34959A (es) Dihidropiridona p1 como inhibidores del factor xia
EA201792021A1 (ru) Ингибитор jak
CL2018001210A1 (es) Compuestos de criptoficina novedosos y productos conjugados, su preparación y su uso terapéutico.
CL2019003515A1 (es) Compuestos heteroaromáticos como inhibidores de vanina.
CY1122381T1 (el) Παραγωγα ιμιδαζοπυριδαζινης ως αναστολεις pi3kbhta
ECSP19013196A (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana
MA52891A (fr) Dérivés aza-indoliques utilisés comme inhibiteurs de rho-kinase
IL290181A (en) Process for the preparation of fluensulfone
LT3924361T (lt) Nauji triterpeno dariniai kaip živ inhibitoriai
MX374813B (es) Análogos de nucleósidos sustituidos para su uso como inhibidores de prmt5.
EA201892188A1 (ru) Соединения пирролотриазина в качестве ингибиторов tam
ECSP11010817A (es) Agentes antifúngicos